BIRC5 and neoplasm: For example, Wand and colleagues tested the therapeutic efficacy of a SOCS1-silenced DC vaccine loaded with two tumor-associated antigens, survivin and MUC-1 in patients with relapsed acute leukemia (AL) after allogenic hematopoietic stem cell transplantation (allo-HSCT).